SLC22A18

Across TCGA pan-cancer cohorts, SLC22A18 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SLC22A18 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher SLC22A18 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC22A18 expression acts as an unfavorable survival marker.

COAD and GBM are the cancer types where SLC22A18 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	IV	0.565	1.000	.028	6	view →
GBM	OS	Median	All	0.739	0.890	.004	5	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

SLC22A18–COAD (DFS)

Open the COAD breakdown →